Production of a rat pancreatic polypeptide-specific monoclonal antibody and its influence on glucose homeostasis by in vivo immunoneutralization

H. C. Wong, Dana Andersen, C. Sternini, C. L. Ruiz, E. C. Hull, J. H. Walsh, F. C. Brunicardi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

To test the effect of endogenous pancreatic polypeptide (PP) on rat hepatic glucose homeostasis by immunoneutralization, a rat PP-specific monoclonal antibody (MAb) was produced. Binding of this IgG1 monoclonal antibody was inhibited 50% by 350 pM rat PP. Immunohistochemistry showed that the antibody produced the expected pattern of endocrine cell staining in rat pancreas. Groups of six adult male Sprague-Dawley rats were given 5 mg of Protein-A-purified anti-PP MAb or anti-KLH MAb (control) ip every 48 hr for 5 dosing intervals. The rate of hepatic glucose output during isolated liver perfusion was 0.25 ± 0.03 mg/g/min for the PP MAb-treated rats and 0.17 ± 0.02 mg/g/min for the control group (p <0.05). Liver glycogen content was 21.8 ± 2.9 mg/g for the PP MAb-treated rats and 14.7 ± 2.4 mg/g for the control group (N = 5). Chronic in vivo immunoneutralization of PP with this new monoclonal antibody suggests that PP influences glucose homeostasis in the rat by affecting hepatic glucose output.

Original languageEnglish (US)
Pages (from-to)369-376
Number of pages8
JournalHybridoma
Volume14
Issue number4
StatePublished - 1995
Externally publishedYes

Fingerprint

Pancreatic Polypeptide
Homeostasis
Monoclonal Antibodies
Glucose
Liver
Control Groups
Liver Glycogen
Endocrine Cells
Staphylococcal Protein A
Sprague Dawley Rats
Pancreas
Perfusion
Immunoglobulin G
Immunohistochemistry
Staining and Labeling
Antibodies

ASJC Scopus subject areas

  • Genetics
  • Immunology

Cite this

Wong, H. C., Andersen, D., Sternini, C., Ruiz, C. L., Hull, E. C., Walsh, J. H., & Brunicardi, F. C. (1995). Production of a rat pancreatic polypeptide-specific monoclonal antibody and its influence on glucose homeostasis by in vivo immunoneutralization. Hybridoma, 14(4), 369-376.

Production of a rat pancreatic polypeptide-specific monoclonal antibody and its influence on glucose homeostasis by in vivo immunoneutralization. / Wong, H. C.; Andersen, Dana; Sternini, C.; Ruiz, C. L.; Hull, E. C.; Walsh, J. H.; Brunicardi, F. C.

In: Hybridoma, Vol. 14, No. 4, 1995, p. 369-376.

Research output: Contribution to journalArticle

Wong, H. C. ; Andersen, Dana ; Sternini, C. ; Ruiz, C. L. ; Hull, E. C. ; Walsh, J. H. ; Brunicardi, F. C. / Production of a rat pancreatic polypeptide-specific monoclonal antibody and its influence on glucose homeostasis by in vivo immunoneutralization. In: Hybridoma. 1995 ; Vol. 14, No. 4. pp. 369-376.
@article{6e462ffb1d5f4026af9da123b813258f,
title = "Production of a rat pancreatic polypeptide-specific monoclonal antibody and its influence on glucose homeostasis by in vivo immunoneutralization",
abstract = "To test the effect of endogenous pancreatic polypeptide (PP) on rat hepatic glucose homeostasis by immunoneutralization, a rat PP-specific monoclonal antibody (MAb) was produced. Binding of this IgG1 monoclonal antibody was inhibited 50{\%} by 350 pM rat PP. Immunohistochemistry showed that the antibody produced the expected pattern of endocrine cell staining in rat pancreas. Groups of six adult male Sprague-Dawley rats were given 5 mg of Protein-A-purified anti-PP MAb or anti-KLH MAb (control) ip every 48 hr for 5 dosing intervals. The rate of hepatic glucose output during isolated liver perfusion was 0.25 ± 0.03 mg/g/min for the PP MAb-treated rats and 0.17 ± 0.02 mg/g/min for the control group (p <0.05). Liver glycogen content was 21.8 ± 2.9 mg/g for the PP MAb-treated rats and 14.7 ± 2.4 mg/g for the control group (N = 5). Chronic in vivo immunoneutralization of PP with this new monoclonal antibody suggests that PP influences glucose homeostasis in the rat by affecting hepatic glucose output.",
author = "Wong, {H. C.} and Dana Andersen and C. Sternini and Ruiz, {C. L.} and Hull, {E. C.} and Walsh, {J. H.} and Brunicardi, {F. C.}",
year = "1995",
language = "English (US)",
volume = "14",
pages = "369--376",
journal = "Monoclonal Antibodies in Immunodiagnosis and Immunotherapy",
issn = "2167-9436",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Production of a rat pancreatic polypeptide-specific monoclonal antibody and its influence on glucose homeostasis by in vivo immunoneutralization

AU - Wong, H. C.

AU - Andersen, Dana

AU - Sternini, C.

AU - Ruiz, C. L.

AU - Hull, E. C.

AU - Walsh, J. H.

AU - Brunicardi, F. C.

PY - 1995

Y1 - 1995

N2 - To test the effect of endogenous pancreatic polypeptide (PP) on rat hepatic glucose homeostasis by immunoneutralization, a rat PP-specific monoclonal antibody (MAb) was produced. Binding of this IgG1 monoclonal antibody was inhibited 50% by 350 pM rat PP. Immunohistochemistry showed that the antibody produced the expected pattern of endocrine cell staining in rat pancreas. Groups of six adult male Sprague-Dawley rats were given 5 mg of Protein-A-purified anti-PP MAb or anti-KLH MAb (control) ip every 48 hr for 5 dosing intervals. The rate of hepatic glucose output during isolated liver perfusion was 0.25 ± 0.03 mg/g/min for the PP MAb-treated rats and 0.17 ± 0.02 mg/g/min for the control group (p <0.05). Liver glycogen content was 21.8 ± 2.9 mg/g for the PP MAb-treated rats and 14.7 ± 2.4 mg/g for the control group (N = 5). Chronic in vivo immunoneutralization of PP with this new monoclonal antibody suggests that PP influences glucose homeostasis in the rat by affecting hepatic glucose output.

AB - To test the effect of endogenous pancreatic polypeptide (PP) on rat hepatic glucose homeostasis by immunoneutralization, a rat PP-specific monoclonal antibody (MAb) was produced. Binding of this IgG1 monoclonal antibody was inhibited 50% by 350 pM rat PP. Immunohistochemistry showed that the antibody produced the expected pattern of endocrine cell staining in rat pancreas. Groups of six adult male Sprague-Dawley rats were given 5 mg of Protein-A-purified anti-PP MAb or anti-KLH MAb (control) ip every 48 hr for 5 dosing intervals. The rate of hepatic glucose output during isolated liver perfusion was 0.25 ± 0.03 mg/g/min for the PP MAb-treated rats and 0.17 ± 0.02 mg/g/min for the control group (p <0.05). Liver glycogen content was 21.8 ± 2.9 mg/g for the PP MAb-treated rats and 14.7 ± 2.4 mg/g for the control group (N = 5). Chronic in vivo immunoneutralization of PP with this new monoclonal antibody suggests that PP influences glucose homeostasis in the rat by affecting hepatic glucose output.

UR - http://www.scopus.com/inward/record.url?scp=0029146175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029146175&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 369

EP - 376

JO - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

JF - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

SN - 2167-9436

IS - 4

ER -